Contineum Therapeutics (CTNM) Current Assets (2023 - 2026)

Contineum Therapeutics' Current Assets history runs 4 years deep, the most recent figure standing at $253.0 million for Q1 2026.

• In Q1 2026, Current Assets rose 31.66% year-over-year to $253.0 million; the TTM figure through Mar 2026 stood at $253.0 million (up 31.66% YoY), while the FY2025 annual figure was $267.9 million, up 29.81% from the prior year.
• Current Assets was $253.0 million for Q1 2026 at Contineum Therapeutics, down from $267.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $267.9 million in Q4 2025 to a low of $119.7 million in Q1 2024.
• Historically, Current Assets has averaged $196.4 million across 4 years, with a median of $199.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Current Assets jumped 61.61% in 2024, then retreated 19.74% in 2025.
• A 4-year view of Current Assets shows it stood at $127.7 million in 2023, then surged by 61.61% to $206.4 million in 2024, then gained by 29.81% to $267.9 million in 2025, then decreased by 5.58% to $253.0 million in 2026.
• The last three Current Assets figures came in at $253.0 million (Q1 2026), $267.9 million (Q4 2025), and $184.9 million (Q3 2025), per Business Quant data.